Patent ID: 6969532

Claim:
A method for treating human inflammatory diseases, tissue damage, stroke, septic shock and cancer by administering into a human body an effective amount of a chemical composition, wherein said chemical composition containing a chemical compound or a derivative of said chemical compound, said chemical compound or said derivative of said chemical compound exhibits concurrent COX-2 and iNOS suppressing activities, and said chemical compound is purified from a cultured medium which is produced from a process comprising the following steps: (a) washing human foreskin fibroblasts with a fresh DMEM medium then incubated in a fresh medium containing 2.5%-10% fetal bovine serum for at least 8 hours to form a proliferating phase medium (PPM); (b) subjecting said proliferating phase medium to a 10-kDa ultrafiltration membrane to separate said proliferating phase medium into a <10 kDa fraction, which passes through said 10-kDa ultrafiltration membrane, and a >10 kDa fraction, which is retained by said 10-kDa ultrafiltration membrane; (c) Chromatographing said <10 kDa fraction on a Superdex 30 column by FPLC to separate said <10 kDa fraction into first, second, third, fourth, and fifth post-FPLC fractions, which are observed as five peaks at a spectra absorbance at 220 nm and numbered based on their elusion times from said Superdex 30 column; (d) Injecting said second post-FPLC fraction into a C 18 column in a HPLC system with a gradient elute from 10% to 50% acetonitrile and water containing 0.1% trifluoroacetic acid, to separate said second post-FPLC fraction into first, second, third, fourth, and fifth post-HPLC fractions, which are observed as five peaks at a spectra absorbance at 220 nm and numbered based on their elusion times from said C 18 column; and (e) collecting said fourth post-HPLC fraction.